Therapeutic efficacy of the thymidine kinase/ganciclovir system on large experimental gliomas: A nuclear magnetic resonance imaging study

Gene Therapy

Volumn 6, Issue 6, 1999, Pages 1030-1037

  Bouali Benazzouz, R ^a   Laine M ^a   Vicat, J M ^a   Boisseau, S ^a   Remy C ^a   Fouilhe N ^a   Thomas, F ^a   Nissou, M F ^a   Benabid, A L ^a   Berger, F ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Large experimental gliomas; NMR imaging; Thymidine kinase ganciclovir system

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TARGETING; GENE THERAPY; GLIOMA; HISTOLOGY; INOCULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TUMOR REGRESSION;

ANIMALS; BRAIN NEOPLASMS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; GANCICLOVIR; GLIOMA; MAGNETIC RESONANCE IMAGING; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 6544234538     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300921     Document Type: Article

References (53)

1. Ahsan H, Neugut AI, Bruce JN. Trends in incidence of primary malignant brain tumors in USA, 1981-1990. Int J Epidemiol 1995; 24: 1078-1085.
2. Walker MD et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Eng J Med 1980; 303: 1323-1329.
3. Mahaley MS Jr et al. National survey of patterns of care for brain-tumor patients. J Neurosurg 1989; 71: 826-836.
4. Kim TS, Hallidary AL, Hedley-Whyte ET, Convey K. Correlates of survival and the Daumans-Duport grading system for astrocytoma. J Neurosurg 1991; 74: 27-37.
5. Black PM. Brain tumors. New Engl J Med 1991; 324: 1555-1564.
6. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
7. Kornblith PK, Welch WC, Bradley MK. The future of therapy for glioblastoma. Surg Neurol 1993; 39: 538-543.
8. Mizuno M, Yoshida J. Gene therapy for brain tumors. Nippon Rinsho 1997; 55: 1853-1860.
9. Hoang-Xuan K, Li YJ, Hamelin R, Delattre O. Molecular biology in cerebral gliomas: recent advances. Rev Neurol (Paris) 1995; 151: 608-618
10. Scheck AC et al. Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme. Clin Cancer Res 1996; 2: 187-199.
11. Ezzedine ZD et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608-614.
12. Chen SH et al. Gene therapy for brain tumors: regression of experimental gliomas with adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
13. Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 1982; 73: 7-13.
14. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
15. Plautz G, Nabel EG, Nabel GJ. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol 1991; 3: 709-715.
16. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
17. Barba D, Hardin J, Ray J, Gage F. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993; 79: 729-735.
18. Izquierdo M et al. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Therapy 1995; 2: 66-69.
19. Maron A et al. Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: long-term follow-up by magnetic resonance imaging. Gene Therapy 1996; 3: 315-322.
20. Zhu J et al. A continuous intracerebral gene delivery system for in vivo liposome-mediated gene therapy. Gene Therapy 1996; 3: 472-476.
21. Sugaya S et al. Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum Gene Ther 1996; 7: 223-230.
22. Tamura M et al. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Hum Gene Ther 1997; 8: 381-391.
23. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
24. Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990; 1: 125-134.
25. Osaki T et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5258-5261.
26. Vile GR, Hart IR. Use of tissue specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.
27. Bonnekoh B et al. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 1995; 104: 313-317.
28. Golumbek PT et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 1992; 12: 224-230.
29. Takamiya Y et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993; 79: 104-110.
30. Cool V et al. Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum Gene Ther 1996; 7: 627-635.
31. Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997; 3: 1354-1361.
32. Deliganis AV et al. Serial MR in gene therapy for recurrent glioblastoma: initial experience and work in progress. Am J Neuroradiol 1997; 18: 1401-1406.
33. Chen CY et al. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the 'bystander effect'. Hum Gene Ther 1995; 6: 1467-1476.
34. Iwadate Y et al. In vivo bystander effect in the intracranial model with rat glioma cells reflects the clonal difference of HSV-TK positive cells. Int J Oncol 1996; 9: 521-525.
35. Beck C et al. The thymidine kinase/ganciclovir-mediated 'suicide' effect is variable in different tumor cells. Hum Gene Ther 1995; 6: 1525-1530.
36. Sturtz FG et al. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy. Hum Gene Ther 1997; 8: 1945-1953.
37. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-8189.
38. Benedetti S et al. Limited Efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther 1997, 8: 1345-1353.
39. Barth RF. Rat brain tumor models in experimental neurooncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998; 36: 91-102.
40. Benabid AL, Remy C, Chauvin C. Experimental models of rat brain tumors by stereotaxic injection of C6 glioma and HTC hepatoma cell lines. In: Walker and Thomas (eds). Biology of Brain Tumor. Martinus Nijhoff: Boston, 1986, pp 221-226.
41. Ram Z et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vaculature and growth of 9L gliomas in rats. J Neurosurg 1994; 81: 256-260.
42. LeMay DR et al. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy. Hum Gene Ther 1998; 9: 989-995.
43. Plate KH, Risau H. Angiogenesis in malignant gliomas. Glia 1995; 15: 339-347.
44. Abina MA et al. Lac Z gene transfer into tumor cells abrogates rumorigenicity and protects mice against the development of further tumors. Gene Therapy 1996; 3: 212-216.
45. Moolten FL, Wells JM, Mroz PJ. Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. Cancer Lett 1992; 64: 257-263.
46. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697-2702.
47. Freeman SM et al. The 'bystander effect' : tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
48. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987; 51: 503-512.
49. Apt KE, Kroth-Pancic PG, Grossman AR. Stable nuclear transformation of the diatom Phaeodactylum tricornutum. Mol Gen Genet 1996; 252: 572-579.
50. Kobayashi NN, Allen N, Clendenon NR, Li-Wen KO. An improved rat brain tumor model. J Neurosurg 1980; 53: 808-815.
51. Fyfe JA et al. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethy) guanine. J Biol Chem 1978; 253: 8721-8727.
52. Montero-Menei CN et al. Liposaccharide intracerebral administration induces minimal inflammatory reaction in rat brain. Brain Res 1994; 653: 101-111.
53. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat 1958; 53: 457-481.